Do you recommend prostate RT for patients with metastatic (M1) disease?  

A recent NCBD analysis (Rusthoven et al, JCO 2016) suggests that the addition of prostate RT significantly improves survival compared to ADT alone in men with M1 disease (propensity score-matched 5-year OS 49% vs 33%, P<0.001). The benefit was limited to men who received ≥65 Gy. Are these data sufficient to consider prostate RT for M1 patients, or is local therapy only indicated to palliate symptomatic disease until the STAMPEDE M1 cohort, as well as other randomized trials, establish a benefit in this setting? If you offer prostate RT to M1 patients, what dose and fractionation do you use?



Answer from: Radiation Oncologist at Academic Institution
Comments
Radiation Oncologist at University of Michigan Medical School
Also the recent HORRAD trial is the only RCT prese...
Radiation Oncologist at Duke University School of Medicine
I think STAMPEDE supports the use of XRT to the pr...
Sign in or Register to read more

Answer from: Radiation Oncologist at Academic Institution
Comments
Radiation Oncologist at Karmanos Cancer Center
I think the answer needs to consider, what is the ...
Sign in or Register to read more

Answer from: Radiation Oncologist at Academic Institution

Answer from: Radiation Oncologist at Academic Institution

Answer from: Radiation Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice

Answer from: Radiation Oncologist at Community Practice

Answer from: Medical Oncologist at Community Practice